NovaBridge Biosciences Sponsored ADS (NBP:NASDAQ) closed at $1.37 on October 23, 2026, up 3.01% on the day. The stock trades 73.6% below its 52-week high of $5.19 and 9.2% above its 52-week low of $1.26. Over the past year, it lost 67.5%. NovaBridge Biosciences Sponsored ADS is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, NBP closed higher on 103 days (41%). Its best day was June 29, 2026 (+20.73%) and its worst was March 30, 2026 (-11.81%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
Find more stocks like NBP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.